Articles tagged "Highly-sensitized"

2020 American Transplant Congress
High PRA Increases Rejection but Does Not Worsen Renal Function in the First Year Post Kidney Transplant with Alemtuzumab Induction
B. Wise, A. Freeman, M. Janusek, S. Anders, L. Hutchinson, U. Kaszubski, D. Marroquin, D. Martin, H. Bohorquez
Ochsner Medical Center, New Orleans, LA
*Purpose: Sensitization is an important immunologic risk factor considered in renal allograft allocation and influences immunosuppression. Unfortunately, there is a lack of consensus regarding the…
2020 American Transplant Congress
Anti-T Lymphocyte Immunoglobulins versus Basiliximab in Highly Sensitized Kidney-Transplant Patients without Preformed DSAs: The Satir Study
N. Kamar¹, L. Couzi², L. Albano³, A. Durrbach⁴, V. Pernin⁵, L. Esposito¹, M. Lequintrec⁵, P. Merville², A. Del Bello¹
¹Toulouse University Hospital, Toulouse, France, ²Bordeaux University Hospital, Bordeaux, France, ³Nice University Hospital, Nice, France, ⁴Henri Mondor University Hospital, Paris, France, ⁵Montpellier University Hospital, Montpellier, France
*Purpose: Two prospective studies that were performed before the era of highly sensitive solid-phase assays have shown a lower incidence of acute rejection in highly…
2020 American Transplant Congress
Development of a New Kidney Paired Donation (KPD) Program: Starting a Domino Chain with a Deceased Donor
L. Furian¹, C. Di Bella², C. Silvestre², F. Neri², F. Tuci², M. Cardillo³, E. Cozzi⁴, P. Rigotti¹
¹Kidney and Pancreas Transplantation Unit, University of Padova, Padua, Italy, ²Kidney and Pancreas Transplantation Unit, University of Padova, Italy, Italy, ³Italian National Transplant Center, Rome, Rome, Italy, ⁴Transplant Immunology Unit, Padova University-Hospital, Padua, Padua, Italy
*Purpose: The option of initiating a domino chain of living donor kidney transplants with a deceased donor (DD) has been proposed but never enforced. The…
2020 American Transplant Congress
Waiting List and Transplant Outcomes of Highly Sensitized Kidney Patients
R. Schmitz, O. K. Jawitz, S. J. Knechtle, A. M. Jackson
Department of Surgery, Duke University Medical Center, Durham, NC
*Purpose: Sensitized kidney transplant candidates represent a growing population on the waiting list. Transplantation of patients with high calculated panel reactive antibody (CPRA) can be…
2020 American Transplant Congress
In-Vivo Application of Ides (Imlifidase) in Nonhuman Primates Results in Xenoreactive Desensitization: A Novel Anti-Humoral Therapy
B. P. Lovasik¹, A. J. Matar¹, D. A. Faber¹, D. V. Mathews¹, C. Breeden¹, S. C. Kim¹, A. J. Tector², A. Robertson³, C. Kjellman³, A. B. Adams¹
¹Emory University School of Medicine, Atlanta, GA, ²University of Miami, Miami, FL, ³HANSA Biopharma, Lund, Sweden
*Purpose: Antibody-mediated rejection is a formidable barrier to xenograft survival. A novel anti-humoral IdeS therapy, which cleaves serum IgG, represents a promising therapy to reduce…
2020 American Transplant Congress
The Clinical Relevance of cPRA in 0-ABDRDQ Mismatched Kidney Transplants
J. H. Lan¹, D. Chang¹, M. Kadatz¹, J. Gill¹, H. M. Gebel², J. S. Gill¹
¹Medicine, Division of Nephrology, University of British Columbia, Vancouver, BC, Canada, ²Pathology, Emory University, Atlanta, GA
*Purpose: The clinical relevance of immune sensitization as measured by cPRA in kidney transplantation remains uncertain.*Methods: We identified 4,057 adult, first, kidney only transplant recipients…
2019 American Transplant Congress
Three-Year Outcomes of Highly-Sensitized Kidney Transplant Recipients Desensitized with Imlifidase (IdeS)
E. Huang¹, J. Choi¹, A. Vo¹, A. Peng¹, R. Najjar¹, S. Sethi¹, C. Kjellman², L. Winstedt², N. Ammerman¹, S. C. Jordan¹
¹Cedars Sinai Medical Center, Los Angeles, CA, ²Hansa Medical, Lund, Sweden
*Purpose: The HLA-incompatible (HLAi) barrier has been traversed using desensitization therapies with IVIg, rituximab and/or plasmapheresis, although antibody-mediated rejection (ABMR) continues to be observed in…
2019 American Transplant Congress
B Cell Derived Exosomes Are Associated with Antibody Mediated Rejection in Kidney Transplant Recipients Desensitized for a Positive Cross-Match
D. Cucchiari¹, V. Tubita², M. J. Ramirez-Bajo², J. Rovira², F. E. Borràs³, L. Carreras-Planella³, A. Hertig⁴, F. Oppenheimer¹, F. Diekmann¹, I. Revuelta¹
¹Renal Transplant Unit, Hospital Clínic, Barcelona, Spain, ²Laboratori Experimental de Nefrologia i Trasplantament, IDIBAPS, Barcelona, Spain, ³REMAR-IVECAT group, IGTP, Badalona, Spain, ⁴Department of Nephrology and Kidney Transplantation, Hôpital Tenon, Paris, France
*Purpose: Kidney transplant recipients undergoing desensitization for a positive cross-match are at very high risk of developing Antibody-Mediated Rejection (AMR). Because of desensitization, peripheral circulating…
2019 American Transplant Congress
Characterization of HLA Antibodies by C3d Assay and IgG Subclasses in Sensitized Kidney Transplant Patients
A. Casillas-Abundis, J. M. Arreola-Guerra, J. Alberu, M. I. Solis-G, L. Llorente, J. Granados, M. Vilatoba, R. Cruz-Martinez, L. Morales-Buenrostro, A. G. Contreras
Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico
*Purpose: To determine the detection rate of IgG subclasses (IgGsc) and C3d-binding HLA-antibodies (abs) in a cohort of highly sensitized kidney transplant patients.*Methods: We evaluated,…
2019 American Transplant Congress
Validation of Gene Expression Signatures Associated with Antibody-Mediated Rejection (ABMR) in Renal Allograft Biopsies (Bx) of HLA-Sensitized Patients
H. Zhang¹, C. C. Nast², N. Ammerman³, A. A. Vo³, S. C. Jordan³, M. Toyoda¹
¹Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, ²Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, ³Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: "Thoroughly validated gene transcripts” in renal Bx was adopted as one of the criteria for ABMR diagnosis in the latest Banff classification. Previously, we…

« Previous Page
1
…
3
4
5
6
7
…
15
Next Page »